| Ytd | 58.59% | |
| 1y | 364.93% |
| Open | 2.60 | Prev Close | 2.62 | Low | 2.52 | High | 2.63 | Mkt Cap | 482.11M |
| Vol | 486.32K | Avg Vol | 2.32M | EPS | -0.29 | P/E | -8.91 | Forward P/E | -2.44 |
| Beta | 0.21 | Short Ratio | 3.05 | Inst. Own | 56.41% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-12 | 50-d Avg | 2.46 | 200-d Avg | 2.06 | 1yr Est | 3.26 |
OVID News
Ovid Therapeutics (OVID) doesn't possess the right combination of the two key ingredients for a like
Oppenheimer analyst Kostas Biliouris maintains Ovid Therapeutics (NASDAQ:OVID) with a Outperform
Ally Bridge Group NY LLC raised its stake in Ovid Therapeutics (NASDAQ: OVID) by 57.9% during the un
ADAR1 Capital Management LLC grew its holdings in Ovid Therapeutics (NASDAQ: OVID) by 6.0% in the un
NEW YORK, July 08, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutic
Ovid Therapeutics is rated a Buy, driven by risk-adjusted undervaluation and a $193 million cash run
Ovid Therapeutics is upgraded from 'Hold' to 'Buy' as OV329 advances past safety hurdles at higher d
U.S. stock futures mixed, Nasdaq 100 falls 200 pts. Rivian (RIVN) drops after public offering announ
NEW YORK, June 04, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutic
NEW YORK, June 03, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutic
Dosed first participant with OV4071, the first-ever oral potassium-chloride cotransporter 2 (KCC2) d
AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC) said on Monday it had received the Silver Award in OVID He
Ovid Therapeutics Inc. (OVID) Discusses KCC2 Deep Dive and Pipeline Advances in CNS Disorders Transc
NEW YORK, April 08, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceuti
Shares of Ovid Therapeutics (NASDAQ: OVID - Get Free Report) have received an average rating of "Buy
Ovid Therapeutics advances OV329, a GABA-AT inhibitor, into Phase 2 for drug-resistant adult focal o
Ovid Therapeutics Inc. (OVID) Q4 2025 Earnings Call Transcript
OV329 may be safer and more potent than existing treatments. A $60M private placement will fund furt
Ovid Therapeutics reported favorable topline safety and tolerability findings from a 7 mg dose cohor
Ovid Therapeutics (OVID) came out with quarterly earnings of $0.06 per share, beating the Zacks Cons
NEW YORK, March 18, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceuti
NEW YORK, March 18, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceuti
During Wednesday's trading, 517 companies set new 52-week lows.
On Tuesday, 838 companies hit new 52-week lows.
On Monday, 149 companies reached new 52-week lows.
On Monday, 198 companies reached new 52-week lows.
Gainers Urovant Sciences Ltd. (NASDAQ: UROV) shares jumped 93.5% to close at $16.02 on Friday aft
Gainers Urovant Sciences Ltd. (NASDAQ: UROV) shares climbed 94% to $16.06 after the company late
Gainers Inari Medical, Inc. (NASDAQ: NARI) shares surged 123.7% to close at $42.51 on Friday afte
Thursday's morning session saw 48 companies set new 52-week highs.
Stocks Which Set New 52-Week Low Yesterday, Tues., Dec. 18, 2018
Stocks Which Set New 52-Week Low Yesterday, Thurs., Dec. 13, 2018
Stocks Which Set New 52-Week Low Yesterday Tues., Nov. 27, 2018
Stocks Which Set New 52-Week Low The Last Trading Session, Wed., Nov. 21, 2018
Stocks Which Set New 52-Week Low Yesterday, Mon., Nov. 19, 2018
Stocks Which Set New 52-Week Low Yesterday, Wed., Nov. 14, 2018
Stocks Which Set New 52-Week Low Yesterday, October 2nd
Stocks Which Set New 52-Week Low Yesterday, September 25th
Stocks Which Set New 52-Week Low Friday, September 21st